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Abstract  
Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma 
(MM) patients. We randomized 662 patients ≥65 years or transplant-ineligible to receive induction 
with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide 
(CPR) or lenalidomide plus low-dose dexamethasone (Rd). The primary endpoint was progression-
free survival (PFS) in triplet (MPR+CPR) vs doublet (Rd) lenalidomide-containing regimens. After 
a median follow-up of 39 months, the median PFS was 22 months for the triplet combinations and 
21 months for the doublet (p=0.284). The median overall survival (OS) was not reached in both 
groups, and the 4-year OS was 67% for the triplet and 58% for the doublet (p=0.709). By 
considering the three treatment arms separately, no difference in outcome was detected between 
MPR, CPR and Rd. The most common grade ≥3 toxicity was neutropenia: 64% in MPR, 29% in 
CPR and 25% in Rd patients (p<0.0001). Grade ≥3 non-hematologic toxicities were similar among 
groups and were mainly infections (6.5-11%), constitutional (3.5-9.5%) and  cardiac (4.5-6%), with 
no difference between the arms. In conclusion, in the overall population, the alkylator-containing 
triplets MPR and CPR were not superior to the alkylator-free doublet Rd, which was associated 
with lower toxicity.  
This study was registered at www.clinicaltrials.gov #NCT01093196. 
 
Keypoint 
 Triplet lenalidomide-based  regimens did not induce any advantage over doublet 
lenalidomide-based regimen in elderly myeloma patients  
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Introduction 
Multiple myeloma (MM) is the second most frequent hematologic cancer, with a median age at 
diagnosis of around 70 years.
1
 MM is still an incurable disease, but novel agents, such as the 
proteasome inhibitor bortezomib and immunomodulatory drugs thalidomide and lenalidomide have 
considerably improved progression-free survival (PFS) and overall survival (OS) of patients.
2-6
 In 
Europe, melphalan-prednisone-thalidomide (MPT) and melphalan-prednisone-bortezomib (VMP) 
are considered the standards of care for MM patients over 65 years of age or not eligible for 
autologous stem cell transplantation.
2,3,7-13
 Recently, two large phase III trials have shown the 
superiority of lenalidomide-containing regimens over the standard treatments approved for the 
treatment elderly patients with newly diagnosed MM.
14,15
 The MM-015 trial showed that the 
combination melphalan-prednisone-lenalidomide (MPR) followed by maintenance with 
lenalidomide (MPR-R) significantly prolonged PFS (31 months) in comparison with melphalan-
prednisone (13 months, p<0.001) or MPR without maintenance (14 months, p<0.001). The major 
benefit was observed in patients 65 to 75 years of age (p=0.001 for treatment-by-age interaction).
14
 
The FIRST trial showed that lenalidomide plus low-dose dexamethasone (Rd) given until disease 
progression was associated with a significant improvement in PFS (25.5 months) when compared 
with melphalan-prednisone-thalidomide (21.2 months) or Rd for a fixed period of 18 months (20.7 
months) (HR for the risk of progression or death was 0.72 for continuous Rd vs MPT and 0.70 for 
continuous Rd vs 18 months of Rd; p<0.001 for both comparisons).The advantage of Rd given 
continuously or for a fixed period was evident both in patients older or younger than 75 years of 
age.
15
  
To date, a formal comparison between a triplet alkylator-containing regimen vs a doublet alkylator-
free regimen, both including lenalidomide, has not been performed yet. In this phase III trial, we 
compared a triplet lenalidomide-containing regimen (MPR or CPR) with a doublet lenalidomide-
containing regimen (Rd), in order to evaluate which was the best drug to combine with 
lenalidomide (alkylating agents or steroids). The primary end-point was PFS with the triplet versus 
the doublet lenalidomide-containing regimens.  
 
Patients and Methods 
Study Patients 
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Patients with newly diagnosed MM ineligible for high-dose therapy plus stem-cell transplantation 
because of age (≥ 65 years) or coexisting comorbidities could be enrolled. Inclusion criteria were 
measurable disease and Karnofsky performance status ≥ 60%. Patients agreed to use contraception 
and women of childbearing age had a pregnancy test before enrollment. Exclusion criteria included 
renal impairment (creatinine level ≥30 ml/min), uncontrolled or severe cardiovascular disease and 
other malignancies within the past 3 years. The study was approved by the institutional review 
board at each of the participating centers. All patients gave written informed consent before 
entering the study, which was performed in accordance with the Declaration of Helsinki. 
 
Study Design and Intervention  
This is a multicenter randomized (1:1:1) phase III clinical trial that involved 58 centers in Italy and 
9 centers in Czech Republic. The primary endpoint was PFS; secondary endpoints included 
response rate, time to the first evidence of response, OS, and incidence of any grade 3 or higher 
adverse events. Per protocol, patients were stratified by age (≤ 75 years vs > 75 years). Based on the 
recent International Myeloma Working Group geriatric score that stratifies patients according to 
their frailty status (fit, intermediate-fitness, and frail),
16
 a post-hoc analysis not prespecified in the 
original protocol including age (≤ 80 vs > 80 years), comorbidities (according to Charlson score) 
and cognitive/physical status (according to the Activities of Daily Living and the Instrumental 
Activities of Daily Living scores) was conducted. The definitions of fit, intermediate-fitness, and 
frail patients based on age, Charlson score, the Activities of Daily Living and the Instrumental 
Activities of Daily Living scores are summarized in the Supplementary Appendix.  
Patients enrolled were randomly allocated to receive induction treatment with nine 28-day cycles of 
MPR (n=217) or CPR (n=220) or Rd (n=217). Upfront dose reductions of dexamethasone, 
melphalan and cyclophosphamide were performed according to patients age. MPR patients received 
lenalidomide 10 mg/day for 21 days; oral melphalan 0.18 mg/Kg for 4 days in patients 65-75 years 
old and 0.13 mg/Kg in those >75 years; prednisone 1.5 mg/Kg for 4 days. CPR patients received 
lenalidomide 10 mg/day for 21 days; oral cyclophosphamide 50 mg every other day for 28 days in 
patients 65-75 years old and 50 mg every other day for 21 days in those >75 years; prednisone 25 
mg every other day. Rd patients received lenalidomide 25 mg/day for 21 days; dexamethasone 40 
mg on days 1,8,15,22 in patients 65-75 years old and 20 mg in those >75 years. After induction, 
patients were randomized to receive maintenance treatment with lenalidomide alone at 10 mg on 
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days 1-21 every 28 days, or in combination with prednisone at 25 mg every other day continuously. 
After the inclusion of the first 120 patients, the protocol was amended to increment the dose of 
lenalidomide and cyclophosphamide in patients 65-75 years old in the CPR group, due to negligible 
toxicities in comparison with the two other treatment arms. CPR induction schedule was changed to 
lenalidomide 25 mg/day for 21 days and oral cyclophosphamide 50 mg/day for 21 days. All new 
patients  randomized to CPR arm received the new schema after the approval of the amendment. 
Treatment was withheld on withdrawal of the patient’s consent, disease progression or the 
occurrence of any grade 4 hematologic adverse events or grade 3-4 non-hematologic adverse event; 
less serious toxicities were managed through established dose-modification guidelines. 
Antithrombotic prophylaxis was mandatory: aspirin or low-molecular weight heparin or warfarin 
were permitted at physician’s discretion.   
 
Assessments of Endpoint 
The primary endpoint was PFS in patients treated with triplet in comparison with those who 
received a doublet combination. PFS was calculated from the time of induction randomization until 
the date of progression, relapse, death from any cause, or the date the patient was last known to be 
in remission. OS in triplet vs doublet was a secondary end-point and was calculated from the time 
of induction randomization until the date of death from any cause or the date the patient was last 
known to be alive. Efficacy and safety assessments were performed every 4 weeks until relapse, or 
until evidence of disease progression, or when clinically indicated. Evaluation of the response to the 
treatments was performed according to the International Response Criteria for Multiple Myeloma.
17
 
Adverse events were graded according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (version 3.0). 
Statistical analysis 
The study was designed as a 2x2 factorial trial, with two main comparisons of PFS: between 
induction regimens (triplet vs doublet); and between maintenance treatments (lenalidomide-
prednisone vs lenalidomide alone). The design of the study was to show superiority of a three-drug 
regimen over a two-drug regimen. A sample size of 640 patients (430 in MPR+CPR group vs 210 
in Rd group) was determined to provide a power of 80% to detect a hazard ratio (HR) of PFS ≤ 0.75 
comparing patients receiving MPR+CPR with those receiving Rd, by using a log-rank test with a 
two-sided alpha of 0.05. An interim analysis of safety was planned when approximately 85 patients 
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had received at least one treatment. Patients were analyzed on an intention-to-treat basis for all 
time-to-event endpoints. Times of observation were censored on November 1, 2014. Response rates 
and safety were analyzed in patients who received at least one dose of study drugs. Response rates 
and the incidence of any adverse event were compared with the χ2 test or Fisher’s exact test when 
appropriate. Survival data were analyzed with the Kaplan-Meier method, and treatment groups were 
compared with the log-rank test. Time to event was expressed as median with interquartile range 
(IQR). The Cox proportional hazard model was used to estimate HR values and the 95% confidence 
interval (CI) for the intention-to-treat population.  
 
Results 
Between August 2009 and September 2012, a total of 662 patients were enrolled. Eight patients 
were excluded from randomization for screening failure (Figure 1). Six hundred fifty-four patients 
were randomly assigned to receive induction with MPR (n=217) or CPR (n=220) or Rd (n=217). 
Baseline demographics and patients characteristics were well balanced among the three groups 
(Table 1). Median age was 74 years in the MPR arm, 73 years in the CPR arm, 74 years in the Rd 
arm. About 25% of patients were classified as frail. At the time of analysis, all patients had 
completed the assigned induction treatment and 402 patients were randomly allocated to 
maintenance treatment. The median duration of treatment was 18 months  (range 1-62 months). 
Efficacy 
After a median follow-up of 39 months, the median PFS was 22 months with the triplet 
combinations and 21 months with the doublet (HR 0.906, CI 0.739-1.111; p=0.344; Figure 2A). 
The median OS was not reached; the 4-year OS was 67% with triplet regimens and 58% with 
doublet (HR 0.945, CI 0.700-1.274; p=0.709; Figure 2B). By comparing the three arms separately, 
the median  PFS was 24 months in the MPR, 20 months in the CPR and 21 months in the Rd groups 
(Figure 3A). The 4-year OS was 65% with MPR, 68% with CPR and 58% with Rd (Figure 3B). 
After nine induction cycles, the overall response rate (at least partial response, PR) was similar in 
the three groups: 71% with MPR, 68% with CPR and 74% with Rd (Table 2).  
A post-hoc analysis according to patient frailty was performed (Supplementary Appendix).  By the 
primary comparison, in fit patients, the median PFS was 23 months with the triplet regimens and 22 
months with the doublet regimen, and the respective 4-year OS was 77% and 57%. In intermediate-
fitness patients, the median PFS was 22 months with the triplets and 20 months with the doublet, 
8 
 
and the 4-year OS was 67% and 72% in the two groups respectively. In frail patients, the median 
PFS was 18 months with the triplet regimens and 22 months with the doublet regimen, and the 4-
year OS was 44% and 50%.    
By comparing the three arms separately, in fit patients, the median PFS was 30 months in MPR, 22 
months in CPR and 22 months in Rd patients (MPR vs Rd: HR= 0.671, CI 0.461-0.976, p=0.037; 
Figure 4A).  The 4-year OS was 77% in both MPR and CPR groups and 57% in the Rd group. In 
intermediate-fitness patients, the median PFS was 19 months in MPR, 23 months in CPR and 20 
months in Rd patients. The 4-year OS was 61% in the MPR arm and 72% both in the CPR and Rd 
arms. In frail patients, the median PFS was 23 in MPR, 14 in CPR  and 22 months in Rd patients. 
The 4-year OS was 43% with MPR, 45% with CPR and 50% with Rd.  
 
Safety 
During the induction treatment, the most frequent grade ≥3 toxicities were hematologic. At least 
one grade ≥3 hematologic adverse event was reported in 68% of MPR, 32% of CPR and in 29% of 
Rd patients (p<0.0001; Table 3). Neutropenic fever occurred in 5 (3%) MPR, 4 CPR (2%) and 2 
(1%) Rd patients. Per protocol, granulocyte colony-stimulating factor (G-CSF) was administered in 
case of febrile neutropenia and grade 3-4 neutropenia. In this study, 57% of MPR, 23% of CPR and 
20% of Rd patients (p<0.0001) received G-CSF, reducing the duration of neutropenia and the risk 
of infections. The rate of at least one grade ≥3 non-hematologic adverse event did not exceed 31% 
in all the three arms. The most frequent grade ≥3 non-hematologic toxicities were infections (11% 
with MPR, 6.5% with CPR and 9% with Rd) constitutional events (9.5% with MPR, 3.5% with 
CPR and 5% with Rd) and cardiac toxicities (4.5% with MPR, 6% with CPR and 6% with Rd), and 
no significant differences were detected among the three arms (Table 3). A very low incidence of  
thromboembolic events were recorded: 3% in the MPR, 5% in the CPR and 2% in the Rd arms. 
Among the 643 evaluable patients, 203 (32%) patients received low molecular weight heparin, 300 
(47%) aspirin, 87 (14%) both, 16 (2%) warfarin and 37 (5%) did not receive any prophylaxis. Grade 
≥3 peripheral neuropathy was not significant in each arm. Thirteen cases of second primary 
malignancies (SPM) were recorded: 7 (3%) in the MPR, 3 (1%) in the CPR and 3 (1%) in the Rd 
groups. Of these, 5 SPM occurred during induction: 3 (1.5%) in the MPR and 2 (1%) in the CPR 
arms. All SPM were solid, but one case of acute lymphoblastic leukemia in the CPR group. Median 
time to SPM occurrence was 15 months (range 5-36 months). The rate of discontinuation due to 
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adverse events was similar in the three arms: 37/211 (18%) in the MPR, 33/220 (15%) in the CPR 
and 30/212 (14%) in the Rd groups. Lenalidomide was reduced in 45 (21%) MPR, 40 (18%) CPR 
and 34 (16%) Rd patients, without significant differences among the three arms. During the 
induction phase, 27 deaths not related to the progression of disease occurred: 8 (4%) in the MPR, 9 
(5%) in the CPR and 10 (4%) in the Rd arms. Nineteen of them were related to the treatment: 5 in 
the MPR (1 sudden death, 3 infections and 1 stroke), 8 in the CPR groups (1 pulmonary embolism, 
5 cardiologic toxicities, 1 stroke, 1 infection) and 6 in the Rd (1 sudden death, 1 decline of general 
condition, 1 stroke and 3 cardiologic toxicities). 
In a post-hoc analysis, the incidence of at least one hematologic adverse event in fit patients was 
75%  for MPR, 34% for CPR patients and 29% in those who received Rd (p=0.0001 for both MPR 
vs Rd and MPR vs CPR). The rate of non-hematologic adverse events was: 25% in MPR, 22% in 
CPR and 27% in Rd patients. The rate of discontinuation due to adverse events was 13% in patients 
treated with MPR, 8% in patients who received CPR and 10% in those who received Rd. Three fit 
patients died due to treatment-related toxicity (one per arm). In intermediate-fitness patients, the 
incidence of hematologic toxicity was 61% in MPR, 33% in CPR and 25% in Rd (MPR vs Rd and 
MPR vs CPR p=0.0001). At least one non-hematologic adverse event occurred in 29% of MPR, 
32% of CPR and 26% of Rd patients. An increased rate of discontinuation due to toxicities was 
detected independently of treatment randomization: 20% with MPR, 13% with CPR and 18% with 
Rd. Two intermediate-fitness patients in the MPR and 2 in the Rd groups died due to treatment-
related toxicities. In frail patients the incidence of at least one hematologic adverse event was 75% 
with MPR, 28% with CPR and 3% with Rd (p=0.0001 for both MPR vs Rd and MPR vs CPR). The 
incidence of non-hematologic toxicities was 47% in MPR, 42% in CPR and 38% in Rd patients. 
Frail patients had the highest rate of discontinuation due to adverse events and this was more 
evident in the alkylator-containing regimens: 23% with MPR, 30% with CPR and 18% with Rd. A 
higher number of frail patients died due to toxicity: 2 in the MPR (2 infections) and 7 in the CPR (5 
cardiologic events, 1 infection, 1 stroke) and 3 in the Rd (3 cardiologic events) groups.   
 
Discussion 
This is the first randomized phase III trial that compared two alkylator-containing triplet regimens 
(MPR and CPR) with an alkylator-free doublet regimen (Rd) in patients with multiple myeloma 
who were ineligible for stem cell transplantation. After a median follow-up of 39 months no PFS 
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difference was noticed between triplet and doublet regimens, thus the hypothesis of the trial has not 
been confirmed. By analyzing the 3 arms separately, we found that the addition of an alkylating 
agent did not lead to any advantage in terms of response and outcome.  
In our study, the median PFS with Rd was slightly shorter than the one reported in the FIRST study 
(25.5 months with continuous Rd and 20.7 months with Rd for 18 months).
15
 In addition, our 
response rate was comparable to one reported in the FIRST trial, where the ORR with Rd was 73%-
75%. However, we reported a complete response rate of 3% with Rd, which is lower than the 15% 
of the FIRST trial. Of note, the median duration of continuous Rd in that trial was 18.4 months, 
while in our study Rd was administered only for 9 months as induction treatment followed by 
maintenance including lenalidomide at lower dose. Maintenance therapy might have had an impact 
on PFS but the current follow-up does not allow to draw definitive conclusions. A future analysis 
with a longer follow-up is planned to better evaluate the impact of maintenance therapy. The more 
intense regimens of the FIRST study induced an increase in the extra-hematologic toxicity. This 
suggests that continuous treatment with Rd can be a valuable option to prolong PFS and to achieve 
a deeper response, and reducing the dose during maintenance can be a valuable strategy to improve 
tolerability.  
In our trial, the major safety concern was the higher hematologic toxicity reported with MPR 
compared with both Rd and CPR (p<0.0001). Non-hematologic adverse events were comparable in 
the three arms, with an incidence not higher than 10%. In the FIRST study, a higher incidence of 
infections (29% in continuous Rd, 22% in Rd 18-months and 17% in MPT) and cardiac events 
(12% in continuous Rd, 7% in Rd 18 months and 9% in MPT) was reported.
15
 This difference could 
be due to the longer administration of dexamethasone in the FIRST trial as compared with our 
study. A more intensive induction treatment with Rd administered for a limited duration (9 months), 
followed by a less intensive, continuous treatment with lenalidomide alone appears a sensible and 
effective choice.   
In our trial, the incidence of SPM (2%) was not higher than the rates reported in other studies with 
lenalidomide-containing regimens. Of note, the incidence was higher with the alkylator-containing 
regimens, with 3 cases of SPM reported in the Rd group versus 10 cases in the MPR and CPR 
groups. This is in line with a previous meta-analysis that demonstrated an increased risk of SPM 
with lenalidomide in combination with melphalan.
18
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Cyclophosphamide showed to be less toxic and associated with a lower risk of SPM than 
melphalan, and thus may be considered an alternative.
18,19
 Nevertheless, we found no particular 
advantage in terms of efficacy with CPR over the two-drug regimen Rd. Despite the amendment, a 
too low dose of cyclophosphamide might have been adopted in our study. Because of this 
limitation, no definitive conclusions can be drawn regarding CPR. To date, in the elderly setting, 
one phase 2 trial has evaluated cyclophosphamide 300 mg/m
2
 in combination with carfilzomib and 
dexamethasone with positive results.
20
 This may provide the rationale for testing this dose also in 
lenalidomide-containing regimens.  
Determining treatment doses only based on age could be a limit. Therefore, we conducted a post-
hoc analysis and classified patients as fit, intermediate-fitness and frail.
16
 With all the limitations of 
a post-hoc analysis, we found a PFS advantage with MPR as compared with Rd (HR 0.671, 
p=0.037) and CPR in fit patients. Intermediate-fitness and frail patients did not benefit from the 
addition of an alkylating agent. Hematologic toxicities were similar in fit, intermediate-fitness and 
frail patients within each treatment arm. MPR was confirmed to be the combination with the highest 
incidence of hematologic adverse events, independently of the patients’ frailty status. On the other 
hand, frailty influenced the risk of non-hematologic toxicities, discontinuation and treatment-related 
deaths. In MPR frail patients, infection was the only cause of death, thus reflecting the marked 
immune depression with this combination; in Rd and CPR frail patients, cardiovascular toxicity was 
the major cause of death, and this is in line with the toxicity profile of the two combinations. 
Nevertheless, caution is necessary when interpreting these data, as the frailty analysis was not 
prespecified, thus no definitive conclusions can be drawn. Future studies including frailty 
evaluation may validate our results. In the real life, a simple geriatric evaluation in the outpatient 
setting can be performed and may be a valuable tool to guide clinicians in the treatment decision 
process.  
In conclusion, this trial showed that in real-life elderly myeloma patients, the alkylator-containing 
triplet regimens MPR or CPR were not superior to the alkylator-free doublet Rd. This is in line with 
the registrational  FIRST study, where Rd has been demonstrated to be effective for all elderly 
patients.
15
   
In the era of novel effective drugs, new attractive therapeutic options are now available and Rd 
should be optimized through the addition of novel agents. Recently the addition of carfilzomib to 
Rd showed to be effective in the relapsed setting,
21
 and results of a phase 1-2 trial demonstrated that 
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this combination is well tolerated and effective also in newly diagnosed patients.
22
 Also monoclonal 
antibodies, such as elotuzumab, showed to be effective in combination with Rd in the relapsed 
setting, and further investigation in the newly diagnosed setting is needed.
23
 In the next future, trials 
will confirm the role of novel agents in this setting, and these agents may increase the treatment 
armamentarium against myeloma. 
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Table 1. Demographics and baseline characteristics of the patients 
Patients characteristics Melphalan-Prednisone-
Lenalidomide 
(n=218) 
Cyclophosphamide-
Prednisone-Lenalidomide 
(n=222) 
Lenalidomide-
dexamethasone 
(n= 222) 
Age (years) 63-91 63-87 50-89 
Median 74 73 74 
> 75 years (%) 86 (39%) 80 (36%) 83 (37%) 
Sex (male) 108 (50%) 106 (48%) 108 (49%) 
Karnofsky score 60-100 60-100 60-100 
Median 80 90 90 
< 80 (%) 52 (24%) 44 (20%) 44 (20%) 
Fitness    
Fit 89 (41%) 98 (44%) 98 (45%) 
Intermediate-fitness 79 (36%) 70 (32%) 57 (26%) 
Frail 49 (23%) 54 (24%) 65 (28%) 
Data missing 1 (1%) 0 2 (1%) 
Clearance creatinine 
(ml/min) 
 
30-168 
 
30-152 
 
30-150 
Median (ml/min) 70 67 65 
International staging 
system score 
   
I 61 (28%) 59 (27%) 62 (28%) 
II 97 (45%) 103 (46%) 99 (45%) 
III 59 (27%) 60 (27%) 60 (27%) 
Missing data 1 (0.5%) 0 1 (0.5%) 
Cytogenetic 
abnormalities at FISH 
   
Data available 163 (75%) 177 (80%) 185 (83%) 
Data missing 55 (25%) 45 (20%) 37 (17%) 
High risk* 38 (17%) 48 (22%) 47 (25%) 
* At least one among deletion17p (del17) or translocation (4;14) [t(4;14)] or translocation (14;16) [t(14;16)] 
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Table 2 Response rates 
Response Melphalan 
Prednisone 
Lenalidomide (n=211) 
Cyclophosphamide 
Prednisone 
Lenalidomide (n=220) 
Lenalidomide 
dexamethasone 
(n= 212) 
Overall response rate  150 (71%) 150 (68%) 157 (74%) 
   Complete Response  7 (3%) 1 (0.5%) 6 (3%) 
   Very Good Partial Response 48 (23%) 44 (20%) 65 (31%) 
   Partial Response 95 (45%) 105 (48%) 86 (41%) 
Stable Disease  51 (24%) 62 (28%) 49 (23%) 
Not Evaluable* 8 (4%) 3 (1%) 5 (2%) 
Progressive disease 2 (1%) 5 (2%) 1 (0.5%) 
Median time to response (months) 2 2 1.8 
 
* Patients not evaluable for not completing first induction cycle: Rd (1 sudden death; 1 death not specified; 1 hearth failure; medical decision; 1 lost at 
follow-up); MPR: (4 adverse events [2 Fever of unknown origin, 1 not specified, 1 diarrhea and renal failure]; 2 lost at follow-up ; 1 death for 
pneumonia and 1 sudden death); CPR (1 withdrawal of consent; 1 death for sepsis; 1 death for atrial fibrillation). 
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Table 3 Grade ≥ 3 adverse events during induction treatment 
 
 
Grade ≥ 3 Adverse Event 
Melphan- Prednisone-
Lenalidomide 
(n= 211) 
Cyclophosphamide 
Prednisone 
Lenalidomide 
(n=220) 
Lenalidomide-
Dexamethasone 
(n=212) 
HEMATOLOGIC     
At least one event 143 (68%) 71 (32%) 61 (29%) 
Anemia 32 (15%) 14 (6%) 9 (4%) 
Neutropenia* 136 (64%) 63 (29%) 52 (25%) 
Thrombocytopenia 37 (18%) 19 (9%) 15 (7%) 
NON-HEMATOLOGIC     
At least one event 66 (31%) 66 (30%) 63 (30%) 
Cardiologic 9 (4.5%) 11 (6%) 13 (6%) 
Arrithmia 2 (1%) 2(1%) 3 (1.5%) 
Acute Myocardial infarction 1 (0.5%) 4(2%) 4 (2%) 
Heart failure 2(1%) 3(1.5%) 4 (2%) 
Other 4(2%) 2(1%) 2 (1%) 
Vascular 7 (3.5%) 12 (5%) 7 (3%) 
Deep Vein 
Thrombosis/Thromboembolism 
6 (3%) 10 (5%) 5 (2%) 
Stroke 1 (0.5%) 2 (1%) 2 (1%) 
Constitutional 19 (9.5%) 7 (3.5%) 11 (5%) 
Fever 10 (5%) 2 (1%) 3 (1.5%) 
Fatigue 6 (3%) 4(2%) 5(2%) 
Other 3 (1.5%) 1(0.5%) 3(1.5%) 
Dermatologic 9 (5%) 17 (8%) 11 (5%) 
Infection 23 (11%) 16 (6.5%) 20 (9%) 
Pneumonia 2 (1%) 6(2.5%) 4(2%) 
Bronchitis 1 (0.5%) 0 3 (1.5%) 
Sepsis 2 (1%) 2 (1%) 2 (1%) 
Enteritis 0 2 (1%) 2 (1%) 
Febrile neutropenia 8 (4%) 4 (2%) 3 (1.5%) 
Viral reactivation 6 (2%) 0 1 (0.5%) 
Other/not specified 4 (1%) 2 (1%) 5 (1%) 
Peripheral Neurolopathy  6 (3%) 6 (3%) 
 
5 (2%) 
Second Primary 
Malignancies 
3 (1.5%) 2 (1%) 0 
Hematologic  0 1 (0.5%) 0 
Solid 3 (1.5%) 1 (0.5%) 0 
Discontinuation due to 
adverse events 
37 (18%) 33 (15%) 30 (14%) 
 
*
G-CSF administration: Rd 43 (20%); MPR 120 (57%); CPR 51 (23%) 
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Figure legend 
Figure 1. Patient disposition 
Figure 2. Kaplan Mayer estimates of progression-free survival (PFS) and overall survival (OS) in the 
doublet non alkylating agent-containing vs triplet alkylating agent-containing regimens vs after a median 
follow-up of 39 months. Panel A shows PFS; the median PFS was 21 months in the non-alkylating agent-
containing doublet vs 22 months in the alkylating agent-containing triplet regimens. Panel B shows OS; the 
4-year OS was 58% in the non-alkylating agent-containing doublet vs 67% in the alkylating agent-containing 
triplet regimens. 
Figure 3. Kaplan Mayer estimates of PFS and OS according to treatment arm. Panel A shows PFS; the 
median PFS was 21 months with Rd, 24 months with MPR, and 20 months with CPR. Panel B shows OS; 
the 4-year OS was 58% with Rd, 65%with MPR, and 68% with CPR. 
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